ASCO: AIs reduce risk of contralateral breast cancer in patients with BRCA mutation

SAN FRANCISCO – The use of aromatase inhibitors (AIs) in the adjuvant setting appears to delay the development of contralateral breast cancer, and this effect was particularly prevalent among breast...